Company intelligence / Profile preview

CdmoGen Co., Ltd.

Cheongju, Chungcheongbuk-do, South Korea

Ownership: Private
Development stage: Preclinical

Overview

CdmoGen’s lead programs include CRG‑01, a first-in-class scAAV-shRNA therapy targeting mTOR for angiogenic eye conditions, and CRG‑02, an AAV-delivered soluble VEGF receptor variant for wet nAMD. The company has completed over 200 GMP manufacturing/testing projects since 2017. Seven new gene therapy pipelines are in development with two entering clinical trials in 2024

Therapeutic areas: Ophthalmology
Modalities: Gene therapeutics (AAV vectors, shRNA-based therapies)Viral vector-based in vivo gene therapeuticsEx vivo gene therapeutics (retroviral and lentiviral vectors)
Industry: Biotech

Drug pipeline

2 assets

CRG-01

Pre-clinical

Indications: Neovascular age-related macular degeneration

1 more asset in the full pipeline.

Request access →

Partnerships

Not explicitly listed; the company has a global network of experts in CGT new drug development and CDMO technology

Beyond the preview

Go deeper on CdmoGen Co., Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CdmoGen Co., Ltd..

Explore the full profile